Published in J Immunol on December 23, 2016
IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology (2017) 0.75
WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncol Lett (2017) 0.75
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 14.95
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med (1998) 5.59
Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol (2010) 4.92
The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One (2008) 4.52
IL-33 reduces the development of atherosclerosis. J Exp Med (2008) 3.59
IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol (2008) 3.31
Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem (2007) 3.11
Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol (2007) 2.99
IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol (2007) 2.93
IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol (2008) 2.83
IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol (2007) 2.38
Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31
The alarmin interleukin-33 drives protective antiviral CD8⁺ T cell responses. Science (2012) 2.10
A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett (1989) 2.07
IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol (2009) 1.92
IL-33 promotes DC development in BM culture by triggering GM-CSF production. Eur J Immunol (2009) 1.74
IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol (2011) 1.72
Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol (2011) 1.66
IL-33/ST2 axis in inflammation and immunopathology. Immunol Res (2012) 1.62
IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol (2011) 1.57
IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 1.52
IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol (2011) 1.32
Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol (2004) 1.29
IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur J Immunol (2010) 1.27
IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol (2012) 1.25
Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer (2013) 1.25
Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res (2014) 1.23
Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J Immunol (2004) 1.23
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol (2013) 1.16
Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology (2010) 1.16
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res (2006) 1.14
ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol (2011) 1.10
Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci (2011) 1.07
Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res (2014) 1.06
Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett (2009) 1.05
STAT1 expression in dendritic cells, but not T cells, is required for immunity to Leishmania major. J Immunol (2007) 1.05
Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett (2013) 1.05
Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL. J Immunol (2009) 1.05
Skin exposure promotes a Th2-dependent sensitization to peanut allergens. J Clin Invest (2014) 1.01
Targeting BRAFV600E in an inducible murine model of melanoma. Am J Pathol (2012) 1.01
Interleukin 33: a switch-hitting cytokine. Curr Opin Immunol (2014) 1.01
The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol (2012) 1.01
Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol (2014) 1.00
High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma. Transl Oncol (2013) 0.95
Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene (2011) 0.93
BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res (2014) 0.93
IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun (2014) 0.90
Special aspects of interleukin-33 and the IL-33 receptor complex. Semin Immunol (2013) 0.89
T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc Natl Acad Sci U S A (2015) 0.89
Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother (2014) 0.85
Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene (2014) 0.85
Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells. J Immunol (2015) 0.78
T-cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein Cell (2017) 0.75
PD-1 abrogates the prolonged persistence of CD8 CAR-T cells with 4-1BB co-stimulation. Signal Transduct Target Ther (2020) 0.75